Announcement of the resolution by the company's
board of directors for the ex-dividend record date of
cash dividends
Date of events
2022/07/26
To which item it meets
paragraph 14
Statement
1.Date of the resolution by the board of directors or
shareholders' meeting, or of the decision by the company:2022/07/26
2.Type (ex-rights or ex-dividend) (please write "Ex-rights",
"Ex-dividend", or "Ex-rights and dividend"):Ex-dividend
3.Type and monetary amount of dividend distribution:
Cash dividend $387,711,468, $2.7 per share.
4.Ex-rights (Ex-dividend) date:2022/08/15
5.Last date before book closure:2022/08/16
6.Book closure starting date:2022/08/17
7.Book closure ending date:2022/08/21
8.Ex-rights (Ex-dividend) record date:2022/08/21
9.Deadline for applying the conversion of the debt voucher:Not Applicable
10.The closure period for the conversion of the debt voucher will
start from the date:Not Applicable
11.The closure period for the conversion of the debt voucher will
end on the date:Not Applicable
12.Payment date of cash dividend distribution:2022/09/02
13.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEngine Inc. published this content on 26 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2022 09:18:05 UTC.
PharmaEngine, Inc. is a Taiwan-based company principally engaged in the development of new drugs, as well as the licensing and sales of products. The Company is developing three new anti-cancer drugs under the brand of ONIVYDE, which are nal-IRI, MM-398 and PEP02. The Company distributes its products mainly to overseas markets,
PHARMAENGINE, INC. 
